EuroPCR 2024: Late-Breaking Science Video Collection

Published: 20 May 2024

  • Views:

    Views Icon 1136

  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Our regular review series View From the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) dives deep into the late-breaking trials of EuroPCR 2023, spotlighting the impactful data.

For short, concise coverage of the key data revealed, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research. 

Hear commentary on the practice-changing trials of EuroPCR 2024 from selected faculty in our Highlights Reviews.

More from this programme

Part 1

Expert Interviews

6 sessions
Self-Expandable Vs Balloon-Expandable Valves & General Vs Local Anesthesia in TAVI: SOLVE-TAVI Watch now
Influence of Pathophysiological Patterns of CAD on PCI Watch now
Ancillary SMART Trial Analyses Watch now
Impact of Diabetes Severity After Abluminus DES+ Stent: ABILITY Watch now
TAVR Vs SAVR in Younger Low-Risk Patients with Severe Aortic Valve Stenosis: NOTION-2 Watch now
1M DAPT Followed by 5M Ticagrelor Monotherapy in ACS with DCB: CAGEFREE II Watch now

Part 2

View from the Thoraxcenter

2 sessions
View from the Thoraxcenter: What's Hot at EuroPCR 24? Watch now
View from the Thoraxcenter: EuroPCR 24 Wrap Up - Part 1 Watch now

Part 3

Highlights Reviews

2 sessions
5 Trials That Will Change My Practice With Dr Mirvat Alasnag Watch now
4 Trials That Will Change My Practice with Dr Bernardo Cortese Watch now

About the episode

EuroPCR 24 - Dr Roxana Mehran (Mount Sinai Hospital, US) outlines the findings of the ABILITY Global Diabetes study onsite at EuroPCR 2024.

The ABILITY study (NCT04236609) aimed to evaluate the efficacy and safety of the Abluminus DES+ Sirolimus Eluting Stent System (SES) as compared to the XIENCE Everolimus Eluting Coronary Stent System in diabetic patients eligible for percutaneous coronary intervention (PCI). Within this patient group, 40% are expected to be affected by multivessel disease, and 30% by acute coronary syndrome.

Interview Questions:

  1. What is the reasoning behind this study?
  2. Could you tell us a bit more about the Abluminus DES+ SES?
  3. What was the patient population and study design?
  4. What are your key findings?
  5. What are your take-home messages for clinicans?
  6. What are the next steps?

Recorded onsite at EuroPCR Conference, Paris, 2024.

Editor: Jordan Rance
Video Specialists: Dan Brent, 
Interviewer: Liam O'Neill

Faculty Biographies

Roxana Mehran

Roxana Mehran

Professor of Medicine, Cardiology and Professor of Population Health Science and Policy

Roxana Mehran is Professor of Medicine, Cardiology and Professor of Population Health Science and Policy at the Icahn School of Medicine at Mount Sinai in New York. She is also Director of Interventional Cardiovascular Research and Clinical Trials at The Zena and Michael A Weiner Cardiovascular Institute at Mount Sinai Hospital where, over the past 5 years, she has led the development of a globally respected data and clinical coordination centre to support large, multicentre, multinational clinical trials designed to help improve outcomes and quality of life for patients undergoing interventional cardiovascular procedures. In recent years, her work has had a special emphasis on gaining a deeper understanding of anticoagulation and antiplatelet regimens post angioplasty and transcatheter valve replacement; and collection and interpretation of sex-specific data in cardiovascular clinical trials.

Roxana serves on editorial board of multiple peer reviewed journals, including …

View full profile

Comments

You must be to comment. If you are not registered, you can register here.